Cargando…

Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene

Werner's syndrome is caused by the inactivation of both WRN alleles and is characterized by premature aging and increased risk of neoplasms, especially those of mesenchymal origins, such as sarcomas. Given the characteristic genomic instability, patients with this syndrome are more susceptible...

Descripción completa

Detalles Bibliográficos
Autores principales: Awni, Beatriz Mendes, Holanda Lopes, Carlos Diego, Harada, Guilherme, Salgues, Alessandra Corte Real, França, Gilmar de Andrade, Testagrossa, Leonardo de Abreu, Queiroz, Marcelo Araujo, Gonçalves e Silva, Adriano, Ferreira, Fabio de Oliveira, Munhoz, Rodrigo Ramella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958610/
https://www.ncbi.nlm.nih.gov/pubmed/35431856
http://dx.doi.org/10.1159/000521624
_version_ 1784676981575516160
author Awni, Beatriz Mendes
Holanda Lopes, Carlos Diego
Harada, Guilherme
Salgues, Alessandra Corte Real
França, Gilmar de Andrade
Testagrossa, Leonardo de Abreu
Queiroz, Marcelo Araujo
Gonçalves e Silva, Adriano
Ferreira, Fabio de Oliveira
Munhoz, Rodrigo Ramella
author_facet Awni, Beatriz Mendes
Holanda Lopes, Carlos Diego
Harada, Guilherme
Salgues, Alessandra Corte Real
França, Gilmar de Andrade
Testagrossa, Leonardo de Abreu
Queiroz, Marcelo Araujo
Gonçalves e Silva, Adriano
Ferreira, Fabio de Oliveira
Munhoz, Rodrigo Ramella
author_sort Awni, Beatriz Mendes
collection PubMed
description Werner's syndrome is caused by the inactivation of both WRN alleles and is characterized by premature aging and increased risk of neoplasms, especially those of mesenchymal origins, such as sarcomas. Given the characteristic genomic instability, patients with this syndrome are more susceptible to develop toxicities when exposed to cytotoxic agents, such as alkylators and anthracyclines. The impact of the monoallelic WRN mutation on treatment-associated toxicities is poorly understood. Here, we report a patient with locally advanced dedifferentiated liposarcoma of the retroperitoneum harboring a heterozygous germline inactivation mutation in the WRN gene, who was treated with a classic regimen of ifosfamide and doxorubicin and developed exacerbated and prolonged hematological and renal toxicities.
format Online
Article
Text
id pubmed-8958610
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-89586102022-04-14 Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene Awni, Beatriz Mendes Holanda Lopes, Carlos Diego Harada, Guilherme Salgues, Alessandra Corte Real França, Gilmar de Andrade Testagrossa, Leonardo de Abreu Queiroz, Marcelo Araujo Gonçalves e Silva, Adriano Ferreira, Fabio de Oliveira Munhoz, Rodrigo Ramella Case Rep Oncol Case Report Werner's syndrome is caused by the inactivation of both WRN alleles and is characterized by premature aging and increased risk of neoplasms, especially those of mesenchymal origins, such as sarcomas. Given the characteristic genomic instability, patients with this syndrome are more susceptible to develop toxicities when exposed to cytotoxic agents, such as alkylators and anthracyclines. The impact of the monoallelic WRN mutation on treatment-associated toxicities is poorly understood. Here, we report a patient with locally advanced dedifferentiated liposarcoma of the retroperitoneum harboring a heterozygous germline inactivation mutation in the WRN gene, who was treated with a classic regimen of ifosfamide and doxorubicin and developed exacerbated and prolonged hematological and renal toxicities. S. Karger AG 2022-03-04 /pmc/articles/PMC8958610/ /pubmed/35431856 http://dx.doi.org/10.1159/000521624 Text en Copyright © 2022 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Awni, Beatriz Mendes
Holanda Lopes, Carlos Diego
Harada, Guilherme
Salgues, Alessandra Corte Real
França, Gilmar de Andrade
Testagrossa, Leonardo de Abreu
Queiroz, Marcelo Araujo
Gonçalves e Silva, Adriano
Ferreira, Fabio de Oliveira
Munhoz, Rodrigo Ramella
Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene
title Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene
title_full Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene
title_fullStr Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene
title_full_unstemmed Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene
title_short Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene
title_sort exacerbated renal and hematologic toxicities to ifosfamide and doxorubicin-based chemotherapy in a patient with retroperitoneal liposarcoma harboring a germline mutation in the wrn gene
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958610/
https://www.ncbi.nlm.nih.gov/pubmed/35431856
http://dx.doi.org/10.1159/000521624
work_keys_str_mv AT awnibeatrizmendes exacerbatedrenalandhematologictoxicitiestoifosfamideanddoxorubicinbasedchemotherapyinapatientwithretroperitonealliposarcomaharboringagermlinemutationinthewrngene
AT holandalopescarlosdiego exacerbatedrenalandhematologictoxicitiestoifosfamideanddoxorubicinbasedchemotherapyinapatientwithretroperitonealliposarcomaharboringagermlinemutationinthewrngene
AT haradaguilherme exacerbatedrenalandhematologictoxicitiestoifosfamideanddoxorubicinbasedchemotherapyinapatientwithretroperitonealliposarcomaharboringagermlinemutationinthewrngene
AT salguesalessandracortereal exacerbatedrenalandhematologictoxicitiestoifosfamideanddoxorubicinbasedchemotherapyinapatientwithretroperitonealliposarcomaharboringagermlinemutationinthewrngene
AT francagilmardeandrade exacerbatedrenalandhematologictoxicitiestoifosfamideanddoxorubicinbasedchemotherapyinapatientwithretroperitonealliposarcomaharboringagermlinemutationinthewrngene
AT testagrossaleonardodeabreu exacerbatedrenalandhematologictoxicitiestoifosfamideanddoxorubicinbasedchemotherapyinapatientwithretroperitonealliposarcomaharboringagermlinemutationinthewrngene
AT queirozmarceloaraujo exacerbatedrenalandhematologictoxicitiestoifosfamideanddoxorubicinbasedchemotherapyinapatientwithretroperitonealliposarcomaharboringagermlinemutationinthewrngene
AT goncalvesesilvaadriano exacerbatedrenalandhematologictoxicitiestoifosfamideanddoxorubicinbasedchemotherapyinapatientwithretroperitonealliposarcomaharboringagermlinemutationinthewrngene
AT ferreirafabiodeoliveira exacerbatedrenalandhematologictoxicitiestoifosfamideanddoxorubicinbasedchemotherapyinapatientwithretroperitonealliposarcomaharboringagermlinemutationinthewrngene
AT munhozrodrigoramella exacerbatedrenalandhematologictoxicitiestoifosfamideanddoxorubicinbasedchemotherapyinapatientwithretroperitonealliposarcomaharboringagermlinemutationinthewrngene